The Centers for Medicare and Medicaid Services recently announced a proposed rule to change the structure of the Comprehensive Care for Joint Replacement model, and cancel the Episodic Payment Model, and Cardiac Rehabilitation incentive payment model.
Pharma giant Mylan will pay $465 million to resolve False Claims Act allegations that Mylan misclassified EpiPen as a generic drug to avoid paying Medicaid rebates owed to it under the Medicaid Drug Rebate Program, according to the United States Attorney’s Office of the District of Massachusetts.
In July, the Department of Justice and the Department of Health and Human Services announced that they had charged more than 400 defendants from across the country in the largest healthcare fraud scheme ever uncovered by the agencies.
The Department of Justice announced that the pharmaceutical manufacturer Celgene has agreed to pay $280 million to settle allegations that the company fraudulently promoted two cancer treatment drugs for uses not approved by the FDA.
Anthem, the largest private insurance company in the United States, has agreed to pay $115 million to settle a class action lawsuit, the consolidation of more than 100 lawsuits filed against it, believed to be the largest settlement ever for a data breach case of this type.